Logo.png
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
18 oct. 2023 08h30 HE | Imunon, Inc.
The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
Emergen logo.png
Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research
14 sept. 2023 09h51 HE | Emergen Research
Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...
MnM_logo_TM_JPG.JPG
Minimal Residual Disease Testing Market is Expected to Reach $2.3 Billion | MarketsandMarkets.
03 août 2023 08h30 HE | MarketsandMarkets Research Pvt. Ltd.
Chicago, Aug. 03, 2023 (GLOBE NEWSWIRE) -- In the near future, the Minimal Residual Disease (MRD) testing industry is poised to experience remarkable growth and transformative advancements. As...
IVS_logo_20160331_CMYK.jpg
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies
21 mai 2019 06h00 HE | Invivoscribe, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics®, today announces expansion of space and...
Actinium Announces N
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
28 juin 2018 08h00 HE | Actinium Pharmaceuticals
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...